📊 SPRY Key Takeaways
Is ARS Pharmaceuticals, Inc. (SPRY) a Good Investment?
ARS Pharmaceuticals faces critical financial distress with only $41.3M in cash supporting approximately 3 months of operations against $170.9M annual operating burn, combined with declining revenue and $96.4M in debt obligations unserviceable from operations. Without immediate capital infusion or dramatic revenue acceleration, the company risks insolvency and severe shareholder dilution.
Why Buy ARS Pharmaceuticals, Inc. Stock? SPRY Key Strengths
- Strong liquidity ratios (7.28x current ratio, 6.48x quick ratio) provide near-term operational flexibility
- Moderate leverage with 0.84x debt-to-equity ratio suggests capital structure not yet severely impaired
- Presence in pharmaceutical sector with potential for high-margin products upon successful commercialization
SPRY Stock Risks: ARS Pharmaceuticals, Inc. Investment Risks
- Critical cash runway of approximately 2.9 months at current burn rate ($41.3M cash vs $170.9M annual operating burn)
- Revenue declining year-over-year (-5.5%) indicating deteriorating market traction despite continued operational investment
- Negative operating income of -$179.4M and inability to service $96.4M debt from operations creates imminent refinancing and equity dilution risk
Key Metrics to Watch
- Monthly cash burn rate and quarters of remaining runway
- Revenue growth acceleration and new product launch performance
- Capital raise announcements, debt restructuring, or strategic partnerships
ARS Pharmaceuticals, Inc. (SPRY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.28x current ratio provides a solid financial cushion.
SPRY Profit Margin, ROE & Profitability Analysis
SPRY vs Healthcare Sector: How ARS Pharmaceuticals, Inc. Compares
How ARS Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ARS Pharmaceuticals, Inc. Stock Overvalued? SPRY Valuation Analysis 2026
Based on fundamental analysis, ARS Pharmaceuticals, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ARS Pharmaceuticals, Inc. Balance Sheet: SPRY Debt, Cash & Liquidity
SPRY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ARS Pharmaceuticals, Inc.'s revenue has grown significantly by 1,519% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.08 reflects profitable operations.
SPRY Revenue Growth, EPS Growth & YoY Performance
SPRY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.1M | -$19.1M | $-0.20 |
| Q2 2025 | $500.0K | -$12.5M | $-0.13 |
| Q1 2025 | N/A | -$10.3M | $-0.11 |
| Q3 2024 | N/A | -$14.9M | $-0.16 |
| Q2 2024 | $10.0K | -$12.5M | $-0.13 |
| Q1 2024 | N/A | -$10.3M | $-0.11 |
| Q3 2023 | N/A | -$6.6M | $-0.16 |
| Q2 2023 | $10.0K | -$6.4M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ARS Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
SPRY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ARS Pharmaceuticals, Inc. (CIK: 0001671858)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SPRY
What is the AI rating for SPRY?
ARS Pharmaceuticals, Inc. (SPRY) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SPRY's key strengths?
Claude: Strong liquidity ratios (7.28x current ratio, 6.48x quick ratio) provide near-term operational flexibility. Moderate leverage with 0.84x debt-to-equity ratio suggests capital structure not yet severely impaired.
What are the risks of investing in SPRY?
Claude: Critical cash runway of approximately 2.9 months at current burn rate ($41.3M cash vs $170.9M annual operating burn). Revenue declining year-over-year (-5.5%) indicating deteriorating market traction despite continued operational investment.
What is SPRY's revenue and growth?
ARS Pharmaceuticals, Inc. reported revenue of $84.3M.
Does SPRY pay dividends?
ARS Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find SPRY SEC filings?
Official SEC filings for ARS Pharmaceuticals, Inc. (CIK: 0001671858) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SPRY's EPS?
ARS Pharmaceuticals, Inc. has a diluted EPS of $-1.74.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SPRY a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, ARS Pharmaceuticals, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SPRY stock overvalued or undervalued?
Valuation metrics for SPRY: ROE of -149.9% (sector avg: 15%), net margin of -203.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SPRY stock in 2026?
Our dual AI analysis gives ARS Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SPRY's free cash flow?
ARS Pharmaceuticals, Inc.'s operating cash flow is $-170.9M, with capital expenditures of $339.0K. FCF margin is -203.1%.
How does SPRY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -203.3% (avg: 12%), ROE -149.9% (avg: 15%), current ratio 7.28 (avg: 2).